西格列汀对2型糖尿病患者阿司匹林抵抗的影响

目的：研究西格列汀对2型糖尿病(Type 2 diabetes mellitus，T2DM)患者阿司匹林抵抗(aspirin resistance，AR)的影响及其机制。方法：从136例T2DM患者选取68例AR患者，随机分成西格列汀组及二甲双胍组，入组前及治疗过程中检测空腹血糖(fasting plasma glucose，FPG)、糖化血红蛋白(glycated hemoglobin，HbAlc)、高敏C反应蛋白(high-sensitivity C reactive protein，hs-CRP)，治疗的第1，3，6，12个月分别检测二磷酸腺苷(adenosine diphosphate，ADP)及花生四烯酸(arachidonic acid，AA)诱导的血小板聚集率(platelet aggregation，PAG)，评价西格列汀对AR的影响。 结果：经降糖治疗6个月后，两组患者FPG和HbAlc基本达标，降糖效果差异无统计学意义(P>0.05)，但西格列汀组患者hs-CRP，ADP及AA诱导的PAG明显下降，与二甲双胍组比较差异有统计学意义(P<0.05)。结论：西格列汀能显著改善T2DM患者的氧化应激炎症状态及AR，且AR的改善可能不依赖于血糖的降低。

Impact of sitagliptin on aspirin resistance in patients with Type 2 diabetes mellitus

Objective: To explore the impact of sitagliptin on aspirin resistance (AR) in patients with Type 2 diabetes mellitus (T2DM). Methods: A total of 68 cases of AR were chosen from 136 cases of T2DM patients. The clinical data, including blood samples, fasting plasma glucose (FPG), glycosylated hemoglobin (HbAlc), and high sensitive C reactive protein (hs-CRP) were collected. Aenosine diphosphate (ADP) and arachidonic acid (AA) -induced platelet aggregation rate (PAG) were detected in 1, 3, 6 and 12 months after the treatment to evaluate the impact of sitagliptin on AR. Results: After 6 months of hypoglycemic treatment, FPG and HbAlc in two groups were at the normal level. The hypoglycemic effect was not obviously different (P>0.05), but the hsCRP and ADP or AA-induced PAG were decreased in the sitagliptin group with statistical significance when compared with the metformin group (P<0.05). Conclusion: Sitagliptin can significantly improve the oxidative stress inflammatory state in T2DM patients and AR, which is independent on blood glucose control.